These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Double sequential defibrillation for out-of-hospital refractory ventricular fibrillation: A scoping review.
    Author: Miraglia D, Miguel LA, Alonso W, Ayala JE.
    Journal: Am J Emerg Med; 2020 Jun; 38(6):1211-1217. PubMed ID: 31937443.
    Abstract:
    BACKGROUND: Double sequential defibrillation (DSD) has been proposed as a viable treatment option for patients in refractory ventricular fibrillation/pulseless ventricular tachycardia (VF/pVT) out-of-hospital cardiac arrests (OHCA). However, currently there is insufficient evidence to support a widespread implementation of this therapy. STUDY OBJECTIVES: The aim of this scoping review was to summarize the current available evidence of DSD for patients with refractory VF/pVT OHCA as well as to identify gaps in the literature that may require further research. METHODS: We conducted a comprehensive literature search of MEDLINE via PubMed, Embase via Ovid, and Scopus on August 19, 2019. We also checked reference lists of relevant papers to identify additional studies. Any controlled clinical study design (randomized controlled trials and non-randomized controlled trials), and observational studies (cohort studies and case-control studies) providing information on resuscitative parameters, survival rates and neurological outcomes in adults (≥ 18 years old) treated with DSD for refractory VF/pVT OHCA were included. Two investigators independently conducted the literature search, study selection, and data extraction. RESULTS: The search yielded 1612 unique records, of which 4 peer-reviewed articles were found relating to the research purpose, totaling 1061 patients of who 20.5% (n = 217) received DSD. Most studies evaluated if pre-hospital DSD was associated with improved survival to discharge after refractory VF/pVT. No randomized controlled trials were identified. CONCLUSION: To date, it is difficult to conclude the real benefit of DSD for patients in refractory VF based on the available evidence. The findings of this scoping review suggest there is limited evidence to support at large-scale the use of DSD for refractory VF/pVT OHCA. Further research is needed to better characterize and understand the use of DSD for refractory VF/pVT, in order to implement best practices to maximize the effectiveness and efficiency of care.
    [Abstract] [Full Text] [Related] [New Search]